11:40 AM EST - Oncolytics Biotech Inc. : announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN® in combination with carboplatin and paclitaxel. Oncolytics Biotech Inc.
shares T.ONC are trading up $0.91 at $4.48.
